Editorial: On the diversity of biological therapeutics ||Free Paper||

Sanjay Awasthi

Professor of Biology and Associate Vice President for Clinical Research at University of North Texas Health Sciences Center; Medical Oncologist, Texas Oncology; Partner, US Oncology

Increasingly precise definition of the molecular nature of disturbances in cellular homeostasis that characterize different disease is leading to an astounding array of novel and effective therapeutics. These are appearing at a rate unrivaled in history. Certainly, not all of these are simply the product of new development. For instance, the idea of enzyme replacement therapy has long roots, but advances in recombinant protein production and delivery techniques have led to successful implementation of enzyme replacement therapy; dosing is being optimized in clinical studies, and it appears that greater benefit will be realized with earlier therapy.